GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NUTEX Investments PLC (BUD:NUTEX) » Definitions » Debt-to-EBITDA

NUTEX Investments (BUD:NUTEX) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is NUTEX Investments Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NUTEX Investments's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was Ft0.00 Mil. NUTEX Investments's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was Ft0.00 Mil. NUTEX Investments's annualized EBITDA for the quarter that ended in Dec. 2023 was Ft405.51 Mil. NUTEX Investments's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NUTEX Investments's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of NUTEX Investments was 8.17. The lowest was -1302.75. And the median was 2.56.

BUD:NUTEX's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful Debt-to-EBITDA only.

NUTEX Investments Debt-to-EBITDA Historical Data

The historical data trend for NUTEX Investments's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NUTEX Investments Debt-to-EBITDA Chart

NUTEX Investments Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NUTEX Investments Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NUTEX Investments's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NUTEX Investments's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NUTEX Investments's Debt-to-EBITDA falls into.



NUTEX Investments Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NUTEX Investments's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 178.064
=0.00

NUTEX Investments's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 405.508
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


NUTEX Investments  (BUD:NUTEX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


NUTEX Investments Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NUTEX Investments's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NUTEX Investments (BUD:NUTEX) Business Description

Traded in Other Exchanges
N/A
Address
Telepes u. 53., Budapest, HUN, 1147
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.

NUTEX Investments (BUD:NUTEX) Headlines

No Headlines